Skip to main content
micro-community-banner
 
  • Saved

Commented on 's Post

Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab era

​ORIGINAL RESEARCH ARTICLE Corresponding Author Departments of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical ..... see more

Source : https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2869

Show More Comments

  • 20 hours 32 min
    This data is consistent with most reports in the rituxan era of the limited value of xrt for most cases of limited stage dlbcl treated with immunochemotherapy
  • Saved

Commented on 's Post

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? - PubMed

1 Special Hospital for Pulmonary Diseases, Rockefellerova 3, 10000 Zagreb, Croatia. Electronic address: dina.rnjak@gmail.com. 2 University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, 10000 Zagreb, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33901641/

Show More Comments

  • 20 hours 33 min
    Given the low seroconversion rates in preliminary reports of covid vaccination in blood cancer patients, this approach makes sense and may be feasible as supply can be enhanced by cryopreservation Show More
  • Saved

Commented on 's Post

Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma - PubMed

1 Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA. 2 Department of Hematology, University Hospital of Essen, Essen, Germany. 3 Department of Radiation Oncology, Stanford University ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33909455/

Show More Comments

  • 20 hours 35 min
    This report makes clinical sense in that more clinically urgent cases, which often have aggressive features such as high disease bulk and advanced stage, would be associated with more circulating Show More
  • Saved

Commented on 's Post

A Case Report of a Primary Conjunctival Diffuse Large B-Cell Lymphoma: Keeping an Eye out Following a Nasopharyngeal Carcinoma - PubMed

Primary diffuse large B cell lymphoma of the conjunctiva is a rare disease. In this article, we report the case of a 40-year-old man who had previously been treated with ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33880260/

Show More Comments

  • 20 hours 37 min
    Many tests were performed to stage this patient other than a pet/ct, which is considered the standard of care for staging dlbcl
  • Saved

Commented on 's Post

Fusarium rhinosinusitis post chimeric antigen receptor T-cell therapy - PubMed

Chimeric antigen receptor T-cell (CAR-T) therapy is a novel treatment for various types of hematologic malignancy. We presented a case of refractory diffuse large B cell lymphoma patient who developed ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33889489/

Show More Comments

  • 20 hours 41 min
    This report would benefit from a more detailed description of anc depression depth and duration as well as steroid dose/duration and prophylaxis of IFI
  • Saved

Commented on 's Post


Key Points
• In the current retrospective study, researchers assessed the safety and efficacy of prophylactic high-dose methotrexate (HD-MTX) with regard to CNS relapse in 258 recently diagnosed ..... see more

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis - PubMed

Despite central nervous system (CNS) relapse occurring in >10% of high-risk diffuse large B-cell lymphoma (DLBCL) patients, the role of CNS-directed prophylaxis is controversial in the absence of randomized controlled ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33881464/

Show More Comments

  • 20 hours 44 min
    This is consistent with other recent studies presented at ash 2020 of the lack of benefit at reducing secondary cns lymphoma with hdmtx prophylaxis. In spite of this, my Show More
  • Saved

Commented on 's Post

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial - PubMed

1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: matasarm@mskcc.org. 2 Centro de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil. 3 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33848462/

Show More Comments

  • 5 days 21 hours
    In a good prognostic subset of relapsed FL, pi3k copa added a pfs gain to rituxan therapy with manageable aes
Mark Fesler Commented on a Post
  • Saved

R/R DLBCL – Novel Treatments & Clinical Experiences

Nearly two-thirds of patients with newly diagnosed DLBCL are cured with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. A minority of those with relapsed disease are candidates for salvage chemotherapy followed by high dose therapy and autologous stem cell transplant (ASCT), however few attain long-term remission. Moreover, those with refractory disease have a median survival of 6 months, which presents a dire need for improved treatments in patients with this deadly presentation.


The emergence of new targeted agents and immunotherapies represents a sea change in the treatment landscape for B-cell lymphomas. Approvals of CAR T-cell therapy, the anti-CD19 monoclonal antibody tafasitamab (Monjuvi), and the antibody-drug conjugate polatuzumab (Polivy) now bring effective treatment options to those with relapsed/refractory disease. Tafasitamab is an Fc-enhanced, anti-CD19 monoclonal antibody that has exhibited single-agent activity in patients with relapsed or refractory B-cell malignancies. It is suggested to act synergistically with lenalidomide (Revlimid), and the immunotherapy dyad of tafasitamab and lenalidomide became the first FDA-approved therapy as second-line treatment of DLBCL. In the Phase II L-MIND study, 80 patients with relapsed/refractory DLBCL who were unsuitable for ASCT, attained an overall response rate (ORR) of 60%, and 43% of patients attained a complete response with a median duration of response 21.7 months and a median progression-free survival (PFS) of 12.1 months. Notably, median overall survival (OS) was not reached. Researchers observed responses in patients with both germinal center and nongerminal center DLBCL and the combination was found to be well tolerated.

What are your experiences with these novel treatments for DLBCL?
How do you advise your patients on prognosis and other concerns related to these novel treatments?

Show More Comments

  • 5 days 21 hours
    Have seen responses in pre and post car T setting and in bmt/car ineligible. Roughly 20% of patients experience durable disease control neuropathy is main concern with polivy Show More
  • Saved

Commented on 's Post

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management - PubMed

Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. FDA: tisagenlecleucel for ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/30528964/

Show More Comments

  • 1 week 2 days
    Key Points • The authors of this article are from the National Cancer institute. They noted that although cytokine release syndrome (CRS) and neurological toxicity are widespread barriers to CAR T-cell therapy, Show More
  • 1 week 2 days
    A nice but already dated review of car T cell landscape with a relevant focus on toxicity management
  • Saved

Commented on 's Post

Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report - PubMed

1 Department of Hematology, Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China. 2 Central Laboratory, Hebei Senlang Biotechnology Co., Shijiazhuang 050000, Hebei ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33869619/

Show More Comments

  • 1 week 2 days
    Thus far there are no proven consolidative or maintenance treatments post CaR T cell therapy, but with continued study one would hope for an emergence of therapies that enhance both Show More
  • Saved

Commented on 's Post

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma - PubMed

doi: 10.1200/JCO.20.03433. Online ahead of print. 1 The University of Texas MD Anderson Cancer Center, Houston, TX. 2 Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland. 3 Levine Cancer ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33683917/

Show More Comments

  • 1 week 2 days
    In cross trial comparison this pi3k inhibitor appears to have less toxicity than its predecessors ...will be nice to see if randomized comparative data emerged to prove this
  • Saved

made a Post

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial - PubMed

1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: matasarm@mskcc.org. 2 Centro de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil. 3 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33848462/

  • Saved

Commented on 's Post

Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma - PubMed

Non-Hodgkin lymphoma (NHL) is a common type of hematological malignant tumor, composed of multiple subtypes that originate from B lymphocytes, T lymphocytes, and natural killer cells. A diagnosis of NHL ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33816315/

Show More Comments

  • 1 week 4 days
    Not aware of a commercially available assay for this but hopefully this type of testing can complement pet/ct for improved response assessment and treatment guidance in the future
  • Saved

Commented on 's Post

Diffuse large B-cell lymphoma: new targets and novel therapies - PubMed

Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33820908/

Show More Comments

  • 1 week 4 days
    Nice review on a rapidly moving therapeutic landscape... providers and patients can have hope for continued improved options in the future
  • Saved

Commented on 's Post

Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: A retrospective single-center study - PubMed

Human immunodeficiency virus (HIV) infection is associated with an increased risk of aggressive lymphoma, especially diffuse large B cell lymphoma (DLBCL). There are few data regarding HIV-associated DLBCL in China. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33854591/

Show More Comments

  • 1 week 5 days
    Nice characterization of a reasonably common clinical entity in a populous country
  • Saved

Commented on 's Post

Composite lymphoma of T-cell rich, histiocyte-rich diffuse large B-cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma: a case report - PubMed

doi: 10.1186/s13256-021-02783-9. 1 Neurology department, Tishreen University hospital, Lattakia, Syria. aseelesber@gmail.com. 2 Faculty of Medicine, Damascus University, Damascus, Syria. 3 Pathology department, Tishreen University hospital, Lattakia, Syria. Free PMC article ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33849639/

Show More Comments

  • 1 week 6 days
    Fascinating... these two diseases are often confused histologically. Impressive work on pathology’s part to recognize two separate but related entities
  • Saved

Commented on 's Post

Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy - PubMed

Cancers, including lymphomas, develop in complex tissue environments where malignant cells actively promote the creation of a pro-tumoral niche that suppresses effective anti-tumor effector T cell responses. Research is revealing ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33842331/

Show More Comments

  • 1 week 6 days
    Study inches closer at finding predictive factors for immune therapy responsiveness , a big unmet need in lymphoma
  • Saved

Commented on 's Post

Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines - PubMed

doi: 10.1186/s12872-021-01996-6. 1 Department of Diagnostic Imaging, Universidade Federal de São Paulo (UNIFESP), Rua Napoleão de Barros 800, Vila Clementino, São Paulo, 04024-002, Brazil. maufbarbosa@gmail.com. 2 Department of Tropical Diseases ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33845778/

Show More Comments

  • 1 week 6 days
    Interesting study focusing on an important problem for a wide range of lymphoma patients receiving anthracycline chemotherapy
  • Saved

Commented on 's Post

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia - PubMed

Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen have emerged as a highly effective treatment option in patients with refractory B-cell hematological malignancies. Safety and efficacy ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33846220/

Show More Comments

  • 2 weeks 1 day
    Key Points • In patients diagnosed with refractory B-cell hematological malignancies, chimeric antigen receptor (CAR) T-cell therapies that target the CD19 antigen have proven highly effective. CAR T-cell therapies work in patients Show More
  • Saved

Commented on 's Post

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma - PubMed

Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCL; TCL) specifically are less ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33822002/

Show More Comments

  • 2 weeks 2 days
    What are the clinical implications of these findings?
  • 2 weeks 4 days
    This is interesting and not surprising as we think alterations in immune status do serve as a nidus for cancer development in general The magnitude of sirs for Show More